Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority ...
The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that of its drugmaking peers.
The layoffs affect Swiss manufacturing facilities. Elsewhere, the FDA pushed back an approval deadline and a mid-stage study ...
The second round of negotiations cuts spending an aggregate 44% over 2024 list prices as the federal government extends ...
In a rapidly heating market, Otsuka is the first to secure FDA clearance for an "anti-APRIL" therapy targeting IgA ...
Itvisma, an intrathecal version of Zolgensma, can be used in children, teens and adults to stabilize or improve motor ...
The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...
The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...
Top executives can steer large pharma companies in many ways. Here are the ones who employees approve of the most.
Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.
The agency is evaluating whether further regulatory action is warranted after receiving reports of neutralizing antibodies.
It’s well known that AD has a strong genetic component. Apolipoprotein E (APOE4) is expressed in 40% to 65% of all AD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback